Membrane KLK2 CHO Cell Line

Membrane KLK2 CHO Cell Line is a clonal CHO cell line stably expressing membrane human KLK2 (kallikrein 2) (NM_005551.5). Surface expression of KLK2 was confirmed by flow cytometry. This cell line was functionally validated in a co-culture assay with Pasritamig (anti-KLK2, anti-CD3 bispecific antibody) by activation of the NFAT Luciferase Reporter Jurkat Cell Line (#60621). Kallikrein-2 (KLK2) is a trypsin-like serine protease. This protein is a member of the glandular kallikrein family and is critical in the enzymatic process as it selectively cleaves the Met-Lys and Arg-Ser bonds in kininogen, thereby releasing Lys-bradykinin. This proteolytic activity contributes to the production of bradykinin, a bioactive peptide with multiple roles in regulating blood pressure, inflammation, and vascular permeability. It is expressed by prostate epithelial cells and it is regulated by the androgen receptor (AR). Its expression in prostate adenocarcinoma is nearly ubiquitous and high expression levels are maintained in metastatic castration-resistant PC (mCRPC). While traditionally seen as secreted, recent research confirms it's also present on the cancer cell surface. Its pattern of expression makes it an ideal target in the treatment of mCRPC using novel therapies, such as radioligands and immune-based therapies like bispecific T cell engagers. Pasritamig is a human bispecific antibody that simultaneously binds to CD3 on T cells and cell surface KLK2 on tumor cells, enhancing the cytotoxicity towards KLK2-expressing tumor cells. A deeper understanding of the role of KLK2 and investigation into therapies will bring benefit to mCRPC patients.